Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-08

Study Completion Date

2022-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase II, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients with Apparent Risk Factors of Nonalcoholic Steatohepatitis (NASH)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

NCT05462353

Non-alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis

ACTIVE_NOT_RECRUITING PHASE2

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034

NASH - Nonalcoholic Steatohepatitis

UNKNOWN PHASE2

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

NCT05842512

Nonalcoholic Steatohepatitis (NASH)

RECRUITING PHASE2

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187

Non Alcoholic Steatohepatitis (NASH)

UNKNOWN PHASE2

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

NCT05118360

Nonalcoholic Steatohepatitis (NASH)

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II, randomized, double blind placebo-controlled, three-arm, parallel-group, intervention clinical trial evaluating anti-oxidant activity of Heptex; a herbal medicinal product of Aerial Parts of Phyllanthus niruri (Dukung Anak) and Fruits of Silybum marianum (Milk Thistle) in patients with apparent risk factors of NASH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonalcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Double blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo (Rice bran) in 2 capsules size 1, administered PO TID on empty stomach with plenty of water.

Group Type PLACEBO_COMPARATOR

Rice bran

Intervention Type OTHER

Placebo

Heptex-low dose

Low dose The contents of one capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.

Group Type EXPERIMENTAL

Heptex

Intervention Type DRUG

Dukung Anak 200 mg + Milk thistle 100 mg

Heptex-high dose

High dose The contents of two capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.

Group Type EXPERIMENTAL

Heptex

Intervention Type DRUG

Dukung Anak 200 mg + Milk thistle 100 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heptex

Dukung Anak 200 mg + Milk thistle 100 mg

Intervention Type DRUG

Rice bran

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged between 18 and 65 years.
2. Both male and female patients who have childbearing potential must agree to practice an acceptable method of birth control during the study and for at least 6 months after the cessation of treatment; such contraceptive methods must include at least one barrier method.
3. Controlled Attenuation Parameter (CAP)-confirmed hepatic steatosis.
4. Patients with elevated serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels but less than 2.5 times the upper limit of the normal range.
5. Liver fibrosis stage F1-F2 as diagnosed by the FibroScan liver stiffness measurement of 5-10 kPa.
6. Liver condition according the following criteria;

* Serum albumin \> 3 g/dl
* INR \< 2
* No ascites on ultrasound
* No documented or suspected hepatic encephalopathy
7. Willing to stop any other liver support and hepatoprotective medications throughout study duration.
8. Able and willing to provide written informed consent.
9. Able and willing to complete all study visits and procedures, including compliance with the requirements and restrictions listed in the consentform.

Exclusion Criteria

1. Pregnant or lactating women.
2. Patients with BMI \> 40 Kg/m2 or BMI \< 18.5 Kg/m2.
3. Serum creatinine \> 1.5 x ULN OR creatinine clearance (GFR) \< 60 mL/minute.
4. Platelet count \< 75,000/mm3.
5. Uncontrolled diabetes mellitus as evident by HbA1c ≥ 8.5%.
6. Patients who are currently receiving Thiazolidinediones.
7. Patients with ischemic heart disease (IHD).
8. History of parenteral nutrition.
9. History of liver transplant.
10. Viral hepatitis, drug-induced liver injury, metabolic liver disease or auto-immune liver disease.
11. Liver cancer or serum alpha-fetoprotein (AFP) \>100ng/ml. Patients with an AFP between 50 and 100ng/ml may be included as long as a liver ultrasound within 3 months of screening, or at screening, shows no evidence of potential hepatocellular cancer.
12. Use of drugs known to induce steatosis (valproate, amiodarone or prednisone) or to affect body weight and carbohydrate metabolism.
13. Use of drugs known to alter liver enzymes.
14. Allergy or allergic history to any of the drug components.
15. History of alcohol abuse as assessed by the investigator within the past 2 years, or an alcohol use pattern that may interfere with the patient's study compliance. Patients must have abstained from alcohol for at least 6 months prior to study start.
16. Patients with history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.
17. Receipt of an investigational drug within 6 months prior to screening, or active enrolment in another investigational medication or device trial.
18. Patients with any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial.
19. Inability to understand and cooperate with the investigators or to give valid consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No